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Background: Although antiretroviral pre-exposure prophylaxis
prevents HIV acquisition, it is not known if it alters HIV disease
progression. This study assesses whether tenofovir gel impacted
on disease progression among CAPRISA 004 microbicide
trial seroconvertors.
Methods: Eighty-three seroconvertors from the tenofovir and placebo
gel arms of the CAPRISA 004 trial were monitored prospectively for
a minimum of 2 years by CD4 count and viral load (VL). Linear mixed
models were fitted to HIV VL, and log rank test was used to compare
time to reach CD4 counts of ,350 cells per microliter.
Results: Median 2-week postinfection VL was 4.74 and 4.45 log
copies per milliliter in women assigned to tenofovir gel (n = 32) and
placebo gel (n = 51) (P = 0.189). Corresponding 12-month post-
infection VLs were 4.24 and 3.70 log copies per milliliter (P =
0.016). After adjusting for clinical and behavioral characteristics
and protective HLA alleles, mean VLs within the first 2 years were
4.51 and 4.02 log copies per milliliter in women from the tenofovir
and placebo arms (P = 0.013). Among women with vaginal tenofovir
measurements, mean VLs were 4.53 and 4.60 log copies per milli-
liter in those with detectable versus undetectable levels (P = 0.840).
Overall mean CD4 counts were 463 and 514 cells per microliter in
women assigned to tenofovir and placebo (P = 0.290). Thirty-two
women (38.6%) reached CD4 counts of ,350 cells per microliter at
median 9.4 months postinfection, 13 (40.6%) from the tenofovir and
19 (37.3%) from the placebo arms (P = 0.786).
Conclusions: Tenofovir gel had no impact on postinfection CD4
counts or the rate of CD4 decline. Although seroconvertors from the
tenofovir arm experienced higher VLs, this did not result in a need
for earlier antiretroviral therapy.
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INTRODUCTION
Randomized controlled clinical trials have demonstrated
that systemic pre-exposure prophylaxis (PrEP) prevents HIV
acquisition in men who have sex with men,1 intravenous drug
users,2 and heterosexual men and women.3,4 This has led to the
licensing of oral tenofovir/emtricitabine (Truvada) as PrEP in
HIV-uninfected individuals at risk of HIV infection. In addi-
tion, the use of antiretrovirals in topical formulations to prevent
HIV acquisition has been actively pursued, but with variable
results,5,6 possibly attributable to differences in adherence
between trials. Although concerns about drug side effects in
healthy individuals,7,8 selection for drug resistance, and risk
compensation have largely been allayed by recent studies,9–11
the effect of failed PrEP on disease course remains an area of
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concern. Animal studies have suggested that macaques, which
acquired Simian/Human Immunodeficiency Virus after failed
PrEP, may have lower acute viremia and be at higher risk for
the acquisition of drug-resistant virus.12,13
Few studies have assessed the effect of PrEP use on
markers of HIV disease progression in individuals who
acquire HIV despite PrEP.14 In the CAPRISA 004 1% teno-
fovir gel microbicide trial,5 women who acquired HIV in the
tenofovir and placebo arms were offered enrollment into the
CAPRISA 002 Acute Infection cohort study.15 Research on
these women from acute HIV infection has already estab-
lished that the diversity of the transmitting virus was similar
between seroconvertors from the 2 arms16 and tenofovir gel
did not seem to select for viruses with enhanced fitness.17
Interestingly, T-cell responses were relatively preserved during
early infection among women who were randomized to receive
tenofovir gel but who seroconverted.18 In addition, sensitive
drug resistance screening of plasma and cervicovaginal lavage
specimen collected during acute HIV infection did not reveal
any PrEP-related tenofovir drug resistance mutations.19
Despite these reassuring findings, data from long-term
follow-up of participants who seroconverted after tenofovir
gel exposure are required to address the safety of topical
PrEP and to alleviate remaining concerns about its imple-
mentation. The CAPRISA 004 trial and the already estab-
lished CAPRISA 002 Acute Infection study provided us with
the opportunity to offer PrEP trial seroconvertors long-term
follow-up. Therefore, the objective of this study was to
compare markers of HIV disease progression among women
who seroconverted during the CAPRISA 004 trial and were
exposed to either 1% vaginal tenofovir gel or placebo.
METHODS
Design and Study Population
Women who acquired HIV infection during the
CAPRISA 004 study, a randomized controlled, double-
blinded trial to assess the safety and effectiveness of the
vaginal microbicide 1% tenofovir gel, were offered enroll-
ment into the CAPRISA 002 Acute Infection cohort study.
Recruitment methods and eligibility criteria for both studies
were previously described in detail.5,15
Briefly, 889 sexually active, HIV-uninfected women
aged 18–40 years from urban and rural settings in South
Africa participated in the CAPRISA 004 study between
May 2007 and March 2010. At each monthly visit, women
tested for HIV with 2 rapid point-of-care antibody tests.
Suspected seroconvertors underwent HIV ribonucleic acid
(RNA) polymerase chain reaction (PCR) and laboratory
enzyme-linked immunosorbent assay testing to confirm the
HIV diagnosis. Product hold was instituted upon confirmation
of HIV acquisition. The date of infection was estimated as the
midpoint between the last negative and first positive antibody
test, or if a woman had tested negative on rapid antibody tests
but positive on retrospective PCR testing, the infection date
was estimated to be 14 days before the positive PCR result.
A total of 98 women acquired HIV during the trial, 38 in
the tenofovir and 60 in the placebo arm. Of these, 83 women
consented to enroll into the CAPRISA 002 study. Participants
were assessed at enrollment and were then followed-up
fortnightly until 3 months, monthly during early infection until
12 months, and 3-monthly, or if medically indicated, thereafter,
until antiretroviral therapy (ART) initiation. Participants had at
least 2 years of follow-up. ART was commenced at a CD4
count of ,350 cells per microliter or an AIDS-defining diag-
nosis, as per South African Adult Treatment Guidelines.20
Demographic and behavioral data were collected in
both studies. Information on sexual behavior, condom, and
contraceptive use and adherence to the 1% tenofovir and
placebo gels was collected in CAPRISA 004 and was
previously reported.11
Laboratory Methods
During the CAPRISA 004 trial, 2 HIV rapid tests,
Determine HIV 1/2 (Abbott Laboratories, Chicago, IL) and
Uni-Gold Recombigen HIV test (Trinity Biotech, Wicklow,
Ireland), were performed at each study visit. Participants with
concordantly positive, discordant, or indeterminate results
were assessed for possible seroconversion by 2 separate RNA
PCR assays (Roche Cobas Amplicor HIV-1 Monitor v1.5;
Roche Diagnostics, Branchburg, NJ), 1 week apart.
Once diagnosed and enrolled, participants had HIV
viral load (VL) and CD4+ T-cell counts using the TruCOUNT
method (BD Biosciences, San Jose, CA) performed at each
visit. During the course of the study, the VL PCR assay
switched from Roche Ampliprep-Amplicor to Roche Taqman
version 1.0 on June 1, 2010, and then to Roche Taqman
version 2.0 on January 9, 2012. All analyses were therefore
adjusted for assay type, and all samples at the critical 12-
month postinfection time point were retested on the Taqman
version 2.0 assay to eliminate potential measurement bias.
The CAPRISA laboratory is accredited by the South African
National Accreditation System (ISO15189).
In addition, all women underwent a genital screen for
sexually transmitted infections (STIs), including herpes
simplex virus (HSV), Chlamydia trachomatis, Neisseria gon-
orrhoeae, Mycoplasma genitalium, Trichomonas vaginalis
PCR and hepatitis B core antibody testing, at enrollment
and 6-monthly during the study. HLA typing at 4-digit reso-
lution was performed using sequence-based typing (Atria
AlleleSEQR kits; Abbott, Chicago, IL). Additional laboratory
and tenofovir drug level data were available from the CAP-
RISA 004 trial.
Plasma samples were tested for antiretroviral drug levels
in seroconvertors with a VL ,400 copies per milliliter at 12-
month postinfection. A liquid chromatography–mass spectrom-
etry (LC-MS/MS) semiquantitative method was used for the
detection of efavirenz, nevirapine, lopinavir, and ritonavir
developed in-house in the Division of Clinical Pharmacology,
University of Cape Town, South Africa. Twenty microliters of
plasma was extracted by protein precipitation and analyzed on
an AB Sciex API 4000 mass spectrometer (AB Sciex, Fra-
mingham, MA). Control samples spiked to the cut-off limits
were analyzed with each batch and used to determine the pres-
ence or absence of the analytes. A deuterated internal standard
was used to monitor the extraction efficiency of the method.
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Outcome Measures
We defined outcomes as follows: (1) a difference in
overall VL measurements and, specifically, at 12 months
postinfection, (2) a difference in overall CD4 count measure-
ments and at 12 months postinfection, and (3) the rate of
disease progression to CD4 count ,350 cells per microliter,
that is, the need for ART initiation. Decline of a CD4 count to
,350 cells per microliter was deemed an endpoint, if it
occurred at least 6 months postinfection to allow for CD4+
T-cell lymphopenia during primary infection that reverted
by 6 months.
Statistical Analysis
Basic descriptive statistics were used to summarize
characteristics of seroconvertors at enrollment. Baseline
differences between women from the tenofovir and placebo
arms were compared using Wilcoxon rank sums and Fisher
exact tests.
CD4 count and HIV VL measurements in the first 2
years of infection, at 3-monthly intervals, were described
using medians and interquartile ranges. The Wilcoxon rank
sum test was used to compare tenofovir and placebo arm
seroconvertors at the specific time points. Linear mixed
models, accounting for repeated measures, were fitted to all
CD4 count and HIV VL measurements in the first 2 years
of infection to assess the impact of CAPRISA 004 arm.
Unadjusted and adjusted analyses were performed controlling
for possible confounders.
Time to CD4 count ,350 cells per microliter was cal-
culated as the period from estimated date of infection to the
date of the first measured CD4 count ,350 cells per micro-
liter beyond 6 months postinfection. Those who did not reach
this low CD4 count were censored at their last postinfection
visit. A Kaplan–Meier survival curve and log rank test was
used to compare the differences between the arms.
Linear mixed models were used to assess the associa-
tion between tenofovir concentrations, as measured in the
genital tract in the CAPRISA 004 study, and VL in the first 2
years of HIV infection.
Statistical analysis was performed using SAS version
9.3 (SAS Institute Inc., Cary, NC), whereas graphs were
prepared using GraphPad Prism 5.
Ethical Considerations
Ethical approval for the CAPRISA 002 study was
obtained from the University of KwaZulu-Natal (E013/04),
the University of Cape Town (025/2004), and the University
of the Witwatersrand (M040202).
RESULTS
Cohort Characteristics by Trial Arm
A total of 83 women of 98 CAPRISA 004 seroconver-
tors (84.7%) consented to participate in the CAPRISA 002
Acute Infection study and have so far contributed 296.1
women-years of ART-naive follow-up with a retention rate of
94.0% and median follow-up time of 48 months (IQR: 31–
57). Recruitment from the 2 trial arms was evenly balanced
with 32 (84.2%) of 38 women from the tenofovir gel PrEP
arm and 51 (85.0%) of 60 women from the placebo arm. Two
thirds of women (67.5%) were diagnosed at the rural and one
third (32.5%) at the urban CAPRISA research sites. The 15
women who did not enroll into the study had similar baseline
characteristics to those who did enroll, apart from reporting
a lower condom use at their last sex act (58.3% vs 84.2%, P =
0.049), and showing lower rates of STI symptoms before
seroconversion (0.0% vs 32.5%, P = 0.005).
At enrollment into the study, the median age was 22
years (IQR: 21–25), most women (81.9%) had had 1 sexual
partner in the previous month with a median of 4 sex-acts per
month (IQR: 2–7), and 61.5% were using depot medroxypro-
gesterone acetate injections as their main method of contra-
ception (Table 1).
The prevalence of STIs (40.7%) and bacterial vaginosis
(55.6%) was high at enrollment. Specifically, 16.1% of
women were diagnosed with C. trachomatis, 6.2% with
N. gonorrhoeae, 8.6% with M. genitalium, and 4.9% with
T. vaginalis. In addition, 11.1% of women tested positive
for HSV by genital fluid PCR.
The median first HIV VL at an estimated median of 2
weeks postinfection was 4.60 log copies per milliliter (IQR:
3.74–5.25) with median of 4.74 log copies per milliliter (IQR:
3.97–5.37) in seroconvertors from the tenofovir arm versus
4.45 log copies per milliliter (IQR: 3.56–5.17) from the pla-
cebo arm (P = 0.189). The median first CD4 count at an
estimated median of 5 weeks (IQR: 3–9) postinfection was
498 cells per microliter (IQR: 393–643) with 467 cells per
microliter (IQR: 380–530) in the tenofovir arm versus 519 cells
per microliter (IQR: 414–689) in the placebo arm (P = 0.106).
Comparing seroconvertors from each trial arm, no
statistically significant differences in baseline characteristics
were found (Table 1).
Seroconvertors Assigned to Tenofovir Gel
Have Higher VLs, but Similar CD4+ T-cell
Counts, Compared to Placebo Recipients
During the First Two Years of Infection
VL measurements remained higher from acute infection
to 24 months postinfection in seroconvertors from the
tenofovir compared with the placebo arm (Fig. 1). The esti-
mated overall mean VL for the tenofovir and placebo arms
were 4.51 log copies per milliliter (SE = 0.20) and 4.02 log
copies per milliliter (SE = 0.19), respectively, during the
course of follow-up (P = 0.013). The difference between arms
was statistically significant by 12 months postinfection, with
a median VL of 4.24 log copies per milliliter (IQR: 3.74–
4.77) versus 3.70 log copies per milliliter (IQR: 2.60–4.66) in
women from the tenofovir and placebo arms, respectively
(P = 0.016) (Table 1). Although, seroconvertors from the
tenofovir arm generally had lower CD4 counts, this difference
did not reach statistical significance at any point during the
24-month follow-up (Table 2). Even after adjusting for poten-
tial confounders including protective HLA types (B*1302,
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B*27, B*57, B*5801, B*8101), there was a strong associa-
tion between assignment to the tenofovir gel arm and post-
infection VL (Table 3). However, no association was
found between trial arm and CD4 count with a mean
CD4 count of 463 cells per microliter (SE = 46.87) in
women from the tenofovir arm compared with 514 cells
per microliter (SE = 45.44) in the placebo arm (P = 0.290)
during the follow-up period (see Figure, Supplemental
Digital Content, http://links.lww.com/QAI/A574).
The multivariate model (Table 3) also revealed a weak
negative association between the number of used gel appli-
cators women returned and the postinfection VL [effect esti-
mate 20.10 (SE = 0.05), P = 0.058] and weak positive
associations between the number of sex acts in the pre-
vious 30 days [0.09 (SE = 0.05), P = 0.079], not using
a condom at the last sex act [0.49 (SE = 0.28), P = 0.078]
and depot medroxyprogesterone acetate use [0.40 (SE =
0.23), P = 0.084].
Because the VL assay changed during the course of
follow-up and, therefore, could have differentially affected
VL estimates, we retested cryopreserved plasma using the
same assay (Taqman version 2.0). The association between
study arm and VLs remained significant: 4.40 versus 3.97 log
copies per milliliter for tenofovir versus placebo women at 12
months postinfection (P = 0.034) (see Table, Supplemental
Digital Content, http://links.lww.com/QAI/A574).
An unusually high proportion of women (12/45, 26.7%)
from the placebo arm had undetectable VLs (,400 copies/
mL) compared with women from the tenofovir arm (1/30,
3.3%) (P = 0.011). Assessment of stored samples from these
women using the more sensitive Taqman version 2.0 assay,
with a lower limit of detection of 20 copies per milliliter,
TABLE 1. Baseline Characteristics of CAPRISA 004 Seroconvertors
Characteristic All (n = 83) Tenofovir arm (n = 32) Placebo arm (n = 51) P*
Median age at seroconversion in years (IQR) 22 (21–25) 23 (20–27) 22 (21–25) 0.460
Median estimated days post infection at CAP002
enrollment (IQR)
37 (24–65) 40 (29–83) 36 (22–59) 0.133
% Rural (n) 67.5% (56) 65.6% (21) 68.6% (35) 0.813
% Sexual partners before seroconversion (n)
More than 1 1.2% (1) 0.0% (0) 2.0% (1) 0.690
1 only 81.9% (68) 78.1% (25) 84.3% (43) —
None 16.9% (14) 21.9% (7) 13.7% (7) —
Median number of sex acts in the past 30 days at visit
before seroconversion (IQR)
4 (2–7) 3 (2–5) 5 (2–7) 0.082
Median number of returned used gels at visit before
seroconversion (IQR)
6 (3–10) 5 (2–10) 8 (4–10) 0.287
Median adherence in 004 (IQR) 59.2% (50%–100%) 56.7% (50%–100%) 60.0% (50%–100%) 0.927
% with condom use at last sex reported at visit before
seroconversion (n)
84.2% (69) 81.3% (26) 86.0% (43) 0.758
% on Depo-Provera at the end of 004 trial (n) 61.5% (51) 59.4% (19) 62.8% (32) 0.819
% with any STI symptoms within 3 months before
seroconversion (n)
32.5% (27) 34.4% (11) 31.4% (16) 0.813
HSV-2 status during 004 trial
% Baseline positive (n) 56.6% (47) 53.1% (17) 58.8% (30)
% Stayed negative (n) 24.1% (20) 25.0% (8) 23.5% (12) 0.866
% Became positive (n) 19.3% (16) 21.9% (7) 17.7% (9)
% BV at CAP002 enrollment† (n) 55.6% (45/81) 62.5% (20) 51.0% (25/49) 0.365
% Trichomonas vaginalis at CAP002 enrollment† (n) 4.9% (4/81) 9.4% (3) 2.0% (1/49) 0.295
% Neisseria gonorrhoeae at CAP002 enrollment† (n) 6.2% (5/81) 3.1% (1) 8.2% (4/49) 0.643
% Chlamydia trachomatis at CAP002 enrollment† (n) 16.1% (13/81) 18.8% (6) 14.3% (7/49) 0.758
%Mycoplasma genitalium at CAP002 enrollment† (n) 8.6% (7/81) 12.5% (4) 6.1% (3/49) 0.426
% HSV-2 PCR at CAP002 enrollment† (n) 11.1% (9/81) 12.5% (4) 10.2% (5/49) 0.734
% with any STI‡ at CAP002 enrollment excluding
BV (n)
40.7% (33/81) 43.8% (14) 38.8% (19/49) 0.817
Median first VL after HIV infection in 004 (log
copies/mL) (IQR)
4.60 (3.75–5.25) 4.74 (3.97–5.37) 4.45 (3.56–5.17) 0.189
Median weeks postinfection at first VL in 004 (IQR) 2 (2–2) 2 (2–3) 2 (2–2) 0.224
Median first CD4 count after HIV infection (IQR) 498 (393–643) 467 (380–530) 519 (414–689) 0.106
Median weeks postinfection at first CD4 count (IQR) 5 (3–9) 6 (4–12) 5 (3–8) 0.159
*P-value calculated using Wilcoxon rank sums test (medians) or Fisher exact tests (proportions).
†Missing STI data at CAPRISA 002 enrollment for 2 participants from the placebo arm.
‡Any STI defined as having either T. vaginalis, N. gonorrhoeae, C. trachomatis, M. genitalium, HSV-2 PCR, or syphilis.
BV, bacterial vaginosis.
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demonstrated that 7 (15.6%) of 45 women versus 1 (3.3%) of
30 women had undetectable VLs (P = 0.134) (see Table, Sup-
plemental Digital Content, http://links.lww.com/QAI/A574).
Further analysis of longitudinal data on the 13 women
with VL ,400 copies per milliliter at 12 months have re-
vealed that 2 women have remained virologically suppressed
and 3 are viremia controllers (VL ,2000 copies per millili-
ter). The remaining women have lost virological control.
Antiretroviral drugs (efavirenz, nevirapine, lopinavir, and ri-
tonavir) were undetectable in plasma samples from these 13
women with low VLs, therefore excluding undisclosed
ART use.
Genital Tract Tenofovir Levels at Time of
Seroconversion are not Associated With VL
Among women from the tenofovir gel arm of the
CAPRISA 004 study, 32 participants had at least 1 tenofovir
level measurement from a vaginal aspirate sample measured
during preinfection or at first visit postinfection. Mean VL
measurements were 4.53 (SE = 0.27) and 4.60 (SE = 0.31) log
copies per milliliter in women with detectable versus unde-
tectable tenofovir levels (P = 0.840). Participants with detect-
able and those with undetectable tenofovir levels had a mean
CD4 count of 499 cells per microliter (SE = 87.84) and 570
cells per microliter (SE = 101.06), respectively (P = 0.556).
Women Who Received Tenofovir and Placebo
Gel Have Similar Rates of HIV
Disease Progression
Of the 83 women, 32 (38.6%) reached the main
endpoint of 2 consecutive CD4 counts ,350 cells per micro-
liter, that is, 13 (40.6%) in the tenofovir arm and 19 (37.3%)
in the placebo arm (Fig. 2). This happened at a median of 9.4
months (IQR: 5.8–12.5) postinfection. There was no associ-
ation between trial arms and time of reaching CD4 count
,350 cells per microliter (P = 0.786).
DISCUSSION
Women assigned to tenofovir gel did not have altered
HIV disease course, which is an important consideration for
topical PrEP rollout. This prospective cohort study found
higher HIV VLs among CAPRISA 004 seroconvertors from
the tenofovir gel arm compared with the placebo arm.
TABLE 2. Comparison of HIV VL and CD4 Count at 3-Monthly Intervals Postinfection
Month 3 6 9 12 15 18 21 24
VL (log copies/mL)
Tenofovir



































P* 0.154 0.065 0.055 0.016 0.189 0.122 0.351 0.189
CD4 count (cells/mL)
Tenofovir



































P* 0.475 0.487 0.629 0.323 0.181 0.512 0.331 1.000
*Wilcoxon rank sums test.
FIGURE 1. Scatterplot of VL measurements within the first 2
years of HIV infection, with a Loess smoothing line and 95%
confidence intervals, stratified by CAPRISA 004 tenofovir gel
and placebo arms.
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However, there was no corresponding difference in CD4
counts or earlier need for ART initiation comparing these 2
groups of seroconvertors. The difference in VL was only
partially explained by a higher proportion of women with
protective HLA alleles among women from the placebo arm.
In addition, the study did not find a dose–response effect
when comparing the presence of genital tract tenofovir
with VL or CD4 counts. Therefore, although tenofovir gel
prophylaxis may be associated with higher VLs, this does
not translate into differences in HIV disease course.
This is one of the first human studies reporting on long-
term follow-up of individuals who seroconverted after expo-
sure to PrEP. Markers of disease progression and possible
confounding characteristics were systematically and prospec-
tively collected and retention rates in the study remain high.
The main limitation of this study is possible selection
bias. The CAPRISA 004 trial showed a 39% effectiveness of
the 1% tenofovir gel, thereby protecting some women
participating in the tenofovir arm from HIV infection. Once
HIV was diagnosed, women were no longer randomized and
important population differences may have been selected, as
evidenced, for example, by some differences in HLA alleles
between women who seroconverted in the 2 arms. Despite
this limitation, comparison of baseline demographic, behav-
ioral, and clinical characteristics revealed no obvious differ-
ences; thus, any differences must have been subtle or not
studied. One of these differences may have been the level of
genital tract inflammation at the time of transmission, which
was measured to be significantly higher in tenofovir arm
seroconvertors, and is most likely one of the main reasons for
tenofovir gel failure in well-adherent women.20
A recent study by Chirwa et al14 reported on follow-up
of 33 seroconvertors (9 assigned to tenofovir/emtricitabine
and 24 to placebo) from the TDF2 oral PrEP trial. This smaller
study found no significant differences in the CD4 count or VL
profiles after 2 years of follow-up. Although, to our knowl-
edge, there are no other studies in humans, several macaque
monkey studies have previously looked at the period imme-
diately after SHIV acquisition in oral PrEP exposed animals.
TABLE 3. Univariate and Multivariate Linear Mixed Model Fitted to HIV VL Within the First 24 Months of Infection
Variable
Univariate Analysis* Multivariate Analysis
Effect Estimate (SE) P Effect Estimate (SE) P
Tenofovir vs placebo 0.38 (0.20) 0.059 0.50 (0.20) 0.013
Age (years) 20.02 (0.02) 0.373 20.02 (0.03) 0.438
Rural vs urban site 0.25 (0.21) 0.229 0.08 (0.26) 0.745
DMPA vs no DMPA† 0.16 (0.20) 0.423 0.40 (0.23) 0.084
Condom used at last sex act † (no vs yes) 0.42 (0.27) 0.127 0.49 (0.28) 0.078
Number of sexual partners† 0.29 (0.25) 0.244 0.39 (0.34) 0.255
Number of returned used applicators† 20.01 (0.02) 0.519 20.10 (0.05) 0.058
Number of sex acts in the past 30 days† 0.01 (0.02) 0.578 0.09 (0.05) 0.079
Median gel adherence in 004 20.003 (0.004) 0.4436 0.003 (0.005) 0.636
STI symptoms within 3 months before
seroconversion (yes vs. no)
20.12 (0.21) 0.562 20.22 (0.23) 0.333
HSV2 status in 004
Baseline positive vs remained negative 20.04 (0.24) 0.857 20.002 (0.26) 0.995
Became positive vs remained negative 0.49 (0.30) 0.106 0.40 (0.31) 0.197
Bacterial vaginosis at 002 enrollment
(positive vs negative)
20.04 (0.20) 0.844 20.14 (0.22) 0.511
Any STI‡ at 002 enrollment (yes vs no) 20.11 (0.20) 0.598 20.36 (0.22) 0.094
Protective HLA-B type§ (yes vs no) 20.47 (0.22) 0.036 20.35 (0.23) 0.141
*All univariate analyses were adjusted for time postinfection and VL assay used (Taqman1 vs Amplicor).
†As reported at last visit before HIV infection in 004.
‡Any STI is defined as having Trichomonas vaginalis, Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, HSV-2 PCR, or syphilis.
§Protective HLA-B types defined as B*1302, B*27, B*57, B*5801, B*8101.
DMPA, depot medroxyprogesterone acetate.
FIGURE 2. Kaplan–Meier graph of time to CD4 count ,350
cells per microliter stratified by CAPRISA 004 arm.
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Zheng et al21 found that PrEP was limiting early virus evolu-
tion most likely because of the direct antiviral effect of PrEP
and/or reduced target cell availability. Kersh et al12 reported
a 100-fold lower peak viremia and reduced systemic inflam-
mation in their macaque model after oral tenofovir/emtricita-
bine PrEP exposure. Furthermore, PrEP-treated macaques
showed no significant CD4 cell count reduction during acute
infection and developed more SHIV-specific central memory
T cells relative to control macaques.
Similar to Kersh et al,12 a study by Curtis et al22 found
a lower peak viremia during acute infection in tenofovir/
emtricitabine-exposed macaques. Interestingly, although the
timing of seroconversion, SHIV binding, and neutralizing anti-
body levels were not impacted by treatment, lower maturation
rates of antibody avidity for anti-p27, gp120, gp160, and gp41
were observed. Whether this could have led to higher VLs later
on during the course of SHIV infection is not known. Further-
more, it is important to remember that these studies were all
conducted with oral PrEP and in animals. Whether these find-
ings also hold true in humans exposed to a 1% tenofovir gel
microbicide is currently unknown.
Potential mechanisms for an increased VL after tenofovir
gel failure could include a selection of fitter viruses at HIV
acquisition, although preliminary studies do not support this,
higher genital and systemic genital tract inflammation driving
higher VLs, or a delay in VL decline after acute infection. To
unravel whether the difference in VL in this study is a direct
effect of PrEP or because of the selection of 2 distinct cohorts
after tenofovir gel exposure, further studies are underway. We
have already established that the diversity, fitness, and resistance
pattern of the transmitted virus, as well as T-cell responses16–19
were not adversely affected by 1% tenofovir gel exposure and
are currently investigating whether a delay in the antibody
response of women who used the tenofovir gel could have been
a contributing mechanism to explain the difference in VLs.
At the same time, long-term clinical follow-up of
participants in this study will continue as part of the
CAPRISA 002 study, and in the CAPRISA 009 study, an
open-label randomized controlled trial (clinicaltrials.gov ref #
NCT01387022) to assess the impact of prophylactic exposure
to tenofovir gel on the efficacy of subsequent tenofovir-
containing ART on viral suppression.
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